Sign In
Buy ATAI
$4.53
-0.280 (-5.82%)
At Close: Jun 03, 2026
Thiel-backed psychedelics startup Atai valued at $3.19 billion in Nasdaq debut
12:16pm, Friday, 18'th Jun 2021
(Reuters) -Shares of Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, surged 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capital
Atai Life Sciences founder on using psychedelics to treat mental illness
10:13am, Friday, 18'th Jun 2021
Atai Life Sciences, a biotech company that uses psychedelics to treat mental illness, is going public on the Nasdaq Friday. Christian Angermayer, Atai Life Sciences founder, joined "Squawk Box" on Fri
atai Life Sciences Announces Pricing of Upsized Initial Public Offering
11:21pm, Thursday, 17'th Jun 2021
BERLIN, June 17, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences B.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,
